Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
  
  • Email Email
  • Comments Comments
  •  (1)
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

Commentary & Opinion

HIV Markets in Rich, Poor Countries Are Two Distinct Markets

June 1, 2012

HIV drugs have not only "transformed a fatal disease into a chronic one," but "[t]hey have also made HIV a big business," this Economist editorial writes. The editorial examines the market for HIV drugs, writing, "The market is as unusual as it is large, both buoyed by government support and worryingly dependent on it. The past decade has brought fancier medicine in rich countries and copious aid for poor ones. But the war is far from won." The editorial writes, "In total, public and private investment has yielded more than two dozen HIV drugs," adding, "Sales of antiretroviral drugs in America and the five biggest European markets reached $13.3 billion in 2011, according to Datamonitor, a research outfit."

The editorial recounts a brief history of HIV drug development, noting, "The rise of combination therapy has brought a flurry of cross-licensing: companies strike deals to sell each other's drugs in carefully calibrated cocktails." It continues, "If the process for developing HIV drugs has been unusual, selling them has been even more so," and discusses the sale and distribution of HIV drugs in both rich and poor countries. The editorial raises the issue of funding through the Global Fund to Fight AIDS, Tuberculosis and Malaria and PEPFAR and highlights a drop in the cost of HIV drugs over time, writing, "Despite the subsidies and the plunge in prices, less than half of those infected with HIV take HIV drugs." It concludes, "There are two distinct HIV markets. In rich countries, many good treatments jostle for market share. ... In poor countries, by contrast, Big Pharma makes very little money but the most efficient copycats thrive. Meanwhile, the world still waits for a cure" (6/2).

Back to other news for June 2012


This information was reprinted from kff.org with permission from the Henry J. Kaiser Family Foundation. You can view the entire Kaiser Daily Global Health Policy Report, search the archives, and sign up for email delivery. © Henry J. Kaiser Family Foundation. All rights reserved.



  
  • Email Email
  • Comments Comments
  •  (1)
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

This article was provided by Henry J. Kaiser Family Foundation. It is a part of the publication Kaiser Daily Global Health Policy Report. Visit the Kaiser Family Foundation's website to find out more about their activities, publications and services.
 
See Also
More on the Economics of HIV Care

 

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)

Your Name:


Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:

Tools
 

Advertisement